MedTrace Logo

A Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 2 Diabetes Mellitus

NCT07794254 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-08-31

No results posted yet for this study

Summary

This Phase I/II clinical trial is a multi-center, single-arm, open-label study aimed at evaluating the safety and efficacy of RGB-5088 islet cell infusion in patients with Type 2 Diabetes Mellitus.

Conditions

  • Diabete Mellitus
  • Diabete Type 2

Interventions

BIOLOGICAL

RGB-5088

Transplantation under the anterior rectus sheath

Sponsors & Collaborators

  • Hangzhou Reprogenix Bioscience, Inc

    lead INDUSTRY

Principal Investigators

  • Linong Ji · Peking University People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-12-30
Completion
2032-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07794254 on ClinicalTrials.gov